ABL1 and leukemia: As may have been expected, administration of the ABL1 allosteric activator, DPH [29], to PD pre-treated leukemia cells significantly enhanced the cytostatic and/or cytotoxic effects of the MEKi in leukemic cell lines containing wild-type abl allele, but not in cells lacking this allele (Fig. 3Ai, ii).